福建海西新药创制股份有限公司 (Fujian Haixi Pharmaceuticals Co. Ltd.) (中国)

The Company was established in the Mainland China in 2012 as a limited liability company under the Company Law of the PRC. The company and its subsidiaries primarily engaged in the businesses of research and development, and manufacture and sale of pharmaceutical products in People's Republic of China (PRC).
HISTORY
Below shows the milestones in the development of the business of the Group:
2012 - The company was established as a limited liability company in the PRC
2014 - The company submitted the application for IND of Azilsartan Tablets to NMPA
2015 - The company submitted the application for IND of Sofosbuvir Tablets to NMPA
2016 - The company obtained the IND approval from NMPA for conducting clinical trials of Azilsartan Tablets in China. The company obtained the IND approval from NMPA for conducting clinical trials of Sofosbuvir Tablets in China. The company were qualified as a High and New Technology Enterprise
2017 - The company were awarded “Fujian Science and Technology Enterprise” by Science and Technology Department of Fujian Province. The company were awarded “New Research and Development Organizations of Fujian Provincial” by Science and Technology Department of Fujian Province
2020 - The company obtained IND approval of C019199 from NMPA in monotherapy and commenced clinical trials for the treatment of various solid tumors. The company obtained the ANDA approval of Anbili in China. The company are the first pharmaceutical company in Fujian Province and among the first five pharmaceutical companies in China to obtain the MAH manufacturing license. The company were awarded with “R D and Transformation Center of Haixi Pharma” by the People's Government of Cangshan District, Fuzhou City
2021 - Anbili was selected in the Fourth National VBP Scheme. The company obtained the ANDA approval of Ruiantuo, Anyoufan and Antuofei in China. Ruiantuo was selected in the Fifth National VBP Scheme
2022 - The company completed Phase Ia clinical trial of C019199 monotherapy. The company commenced Phase Ib/II clinical trial of C019199 monotherapy for osteosarcoma, TGCT and other malignant solid tumors. The company obtained the ANDA approval of Haihuitong, Haibiping in China. The company were awarded the first prize in the “11th China Innovation and Entrepreneurship Competition (Fujian Province)” and the “10th Fujian Innovation and Entrepreneurship Competition”, as well as being recognized as an “Outstanding Enterprise (Growing Enterprise Group)” in the “11th China Innovation and Entrepreneurship Competition”